Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974725 · ClinicalTrials.gov registry record · Phase 1
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 241
- Enrollment target
NCT02974725 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 241 participants.
The verdict
NCT02974725, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 241 participants
- Enrollment target
Study Summary
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
Interventions
- DRUG Ribociclib
- DRUG Trametinib
- DRUG LXH254
- DRUG LTT462
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02974725
The ClinicalTrials.gov registry entry for NCT02974725 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ribociclib is the first listed.
NCT02974725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02974725 about?
NCT02974725 is a clinical study titled "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma". To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
What is the current status of trial NCT02974725?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 241 participants. The study started on 2017-02-24. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT02974725?
The interventions under investigation include: Ribociclib (DRUG), Trametinib (DRUG), LXH254 (DRUG), LTT462 (DRUG).
Who is sponsoring clinical trial NCT02974725?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.